What is Pembrolizumab?

Category: Prescription Drugs

Most popular types: Keytruda

false

Pembrolizumab is a type of specialized, or targeted therapy, that may be used for the treatment of certain types of cancer. It targets the programmed cell death-1 receptor, an action that allows the body's immune system to more easily attack and destroy cancer cells.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Adenocarcinoma (non-small cell lung cancer) 4 1
Melanoma 2 1
Non-small cell lung cancer 2 2
Dry mouth 1 0
Participate in clinical trial 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 4
Mild 0
None 0

Commonly reported side effects and conditions associated with Pembrolizumab

Side effect Patients
Fatigue 4
Achiness 1
Cold intolerance 1
Diarrhea 1
Exhaustion 1
Heart palpitations 1

Show all 12 reported side effects

Dosages

Based on patients currently taking Pembrolizumab

Dosage Patients
25 mg every 3 weeks 2
50 mg every 3 weeks 2
200 mg every 3 weeks 2
25 mg monthly 1
100 mg every 3 weeks 1

Why patients stopped taking Pembrolizumab

Multiple reasons could be selected

Reason Patients
Did not seem to work 2
Other 1
See all 3 patients who've stopped taking Pembrolizumab

Duration

Currently taking Pembrolizumab

Duration Patients
1 - 6 months 1
6 months - 1 year 7
1 - 2 years 1
2 - 5 years 1

Stopped taking Pembrolizumab

Duration Patients
1 - 6 months 2
1 - 2 years 1
Adherence
Adherence Evaluations
Always 4
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 3
Cost per month
Cost per month Evaluations
$200+ 2
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 1

What people switch to and from

Patients started taking Pembrolizumab after stopping:

Treatment Patients
Chemotherapy 1
Erlotinib (Tarceva) 1
Interferon alfa-2a 1
Ipilimumab (Yervoy) 1
Osimertinib (Tagrisso) 1

Show all 6 treatments patients report switching from

Patients stopped taking Pembrolizumab and switched to:

Treatment Patients
Ipilimumab (Yervoy) 2
Docetaxel (Taxotere) 1
Last updated:
There are no evaluations for Pembrolizumab.